TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31009339

Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.4 mg/kg
Number of subjects: 348

Group type: COMPARATOR
Intervention: Alteplase 0.9 mg/kg
Number of subjects: 348
Study: 27521828

Group type: EXPERIMENTAL
Intervention: Brief smoking cessation intervention (protocolized counseling, medications, referrals to a quitline)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Brief smoking cessation intervention
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 156
Study: 24620920

Group type: EXPERIMENTAL
Intervention: ADV in combination with HB‐110
Number of subjects: 27

Group type: COMPARATOR
Intervention: ADV alone
Number of subjects: 27
Study: 23523455

Group type: EXPERIMENTAL
Intervention: IVUS guidance
Number of subjects: 543

Group type: COMPARATOR
Intervention: Angiography guidance
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: IVUS guidance (per-protocol analysis)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Angiography guidance (per-protocol analysis)
Number of subjects: 543
Study: 21757932

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg) injected through the tonsillar capsule
Number of subjects: 78
Study: 19337628

Group type: EXPERIMENTAL
Intervention: Oral Buscopan (20 mg three times a day, n=37)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Buscopan Suppository (30 mg once daily, n=21)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Oral Drotaverine (80 mg three times a day, n=30)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Calcium Gluconate Tablets (one three times a day, n=16)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Calendula Suppository (once daily, n=14)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Oral Buscopan
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Rectal Buscopan
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Oral Drotaverine
Number of subjects: 118
Study: 16426272

Group type: EXPERIMENTAL
Intervention: Patients with a history of atopic disorders
Number of subjects: 186

Group type: COMPARATOR
Intervention: Patients without a history of atopic disorders
Number of subjects: 186
Study: 15294401

Group type: EXPERIMENTAL
Intervention: JUST CD
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 62
Study: 11356239

Group type: EXPERIMENTAL
Intervention: Combined nortriptyline (NT) and interpersonal psychotherapy (IPT)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Monotherapy (either IPT or NT alone)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Maintenance treatment (combined NT and IPT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 8988955

Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Imipramine to Placebo
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (originally treated with Phenelzine)
Number of subjects: 60
Study: 8067244

Group type: COMPARATOR
Intervention: Oxymetazoline spray
Number of subjects: 25

Group type: COMPARATOR
Intervention: Oxymetazoline solution
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 25
Study: 3377149

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of 0.075% bupivacaine at a rate of 12‐18 ml/hour
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intermittent top‐ups of 0.5% bupivacaine
Number of subjects: 73
Study: 4890523

Group type: EXPERIMENTAL
Intervention: Reserpine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Debrisoquine sulphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Methyldopa (high doses)
Number of subjects: 0
Study: 31047902

Group type: EXPERIMENTAL
Intervention: MiniMed 640G system with the suspend‐before‐low feature enabled (intervention group)
Number of subjects: 153

Group type: COMPARATOR
Intervention: MiniMed 640G pump (control group)
Number of subjects: 153
Study: 28659138

Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) and intervention before and during chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard chemotherapy regimens and standard of care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) and intervention
Number of subjects: 0
Study: 27800649

Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 0

Group type: COMPARATOR
Intervention: liraglutide
Number of subjects: 0
Study: 24158583

Group type: EXPERIMENTAL
Intervention: Protecto® sealant
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Light Bond® sealant
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (unsealed quadrant)
Number of subjects: 40
Study: 21627518

Group type: EXPERIMENTAL
Intervention: Nalbuphine HCl (12.5 mg/kg) IV administration
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nalbuphine HCl (12.5 mg/kg) IM administration
Number of subjects: 8
Study: 19531212

Group type: EXPERIMENTAL
Intervention: Letrozole (aromatase inhibitor)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Tamoxifen (anti-estrogen)
Number of subjects: 88

Group type: COMPARATOR
Intervention: COX-2 expression
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Aromatase expression
Number of subjects: 88
Study: 17175400

Group type: EXPERIMENTAL
Intervention: Full individualized feedback condition
Number of subjects: 145

Group type: COMPARATOR
Intervention: Web site access with feedback on stress and coping strategies
Number of subjects: 145
Study: 15531673

Group type: EXPERIMENTAL
Intervention: l‐rhamnose (25 g for 28 days)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: lactulose (25 g for 28 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: d‐glucose (control)
Number of subjects: 11
Study: 11668308

Group type: EXPERIMENTAL
Intervention: Trial-eligible patients (n=197)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Trial-ineligible patients (n=169)
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Overall cohort (n=348)
Number of subjects: 348
Study: 9549960

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 34
Study: 7877519

Group type: EXPERIMENTAL
Intervention: Continuous transdermal oestradiol for 3 months
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cyclical transdermal oestradiol with medroxyprogesterone acetate for 3 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (10 premenopausal women)
Number of subjects: 34
Study: 14552308

Group type: EXPERIMENTAL
Intervention: Auranofin (AF) therapy
Number of subjects: 138
Study: 29530267

Group type: EXPERIMENTAL
Intervention: Guided internet CBT (iCBT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 89
Study: 27846824

Group type: EXPERIMENTAL
Intervention: CenteringPregnancy (CP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual care (Control)
Number of subjects: 0
Study: 25498773

Group type: EXPERIMENTAL
Intervention: RDTs with basic training
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: RDTs with enhanced training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Current practice
Number of subjects: 46
Study: 23460707

Group type: EXPERIMENTAL
Intervention: Single early intravesical instillation of pirarubicin (THP) 30 mg in 30 mL of saline
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no THP instillation)
Number of subjects: 77
Study: 20529344

Group type: EXPERIMENTAL
Intervention: ProADM or proET1 alone
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Adding proADM alone (or all five biomarkers jointly) to the PSI and CURB65 scores
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Models with biomarkers
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Developed prediction models with biomarkers
Number of subjects: 925
Study: 18971890

Group type: EXPERIMENTAL
Intervention: Combined anesthesia with 3-6 microg/kg fentanyl and an epidural bolus of 0.33% bupivacaine followed by a continuous perfusion of 0.175% bupivacaine for up to 48 hours after surgery (TEA group)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Balanced general anesthesia with 7-20 microg/kg fentanyl (GA group)
Number of subjects: 22
Study: 16808800

Group type: EXPERIMENTAL
Intervention: Biatain-Ibu Non-adhesive (Coloplast A/S)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Biatain Non-adhesive (Coloplast A/S)
Number of subjects: 12
Study: 14565739

Group type: EXPERIMENTAL
Intervention: Kangaroo care (skin-to-skin)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 91
Study: 10902988

Group type: EXPERIMENTAL
Intervention: E supplement (1171 kJ + 12 mg iron)
Number of subjects: 136

Group type: COMPARATOR
Intervention: M supplement (209 kJ + 12 mg iron)
Number of subjects: 136

Group type: COMPARATOR
Intervention: S supplement (104 kJ)
Number of subjects: 136
Study: 8883529

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ioxaglate
Number of subjects: 54
Study: 7966600

Group type: EXPERIMENTAL
Intervention: HBV mutants with mutations in the core promoter
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: HBV mutants with mutations in the core promoter alone
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: HBV mutants with mutations in the pre-C region
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: HBV mutants with mutations in both the core promoter and pre-C region
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Mutations in the core promoter
Number of subjects: 57
Study: 3619151

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine caudal anaesthesia (n = 47)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Halothane anesthesia (control group, n = 35)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Comparison between caudal anaesthesia and halothane anesthesia
Number of subjects: 82
Study: 29187694

Group type: EXPERIMENTAL
Intervention: 1 mg/day pitavastatin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 2 mg/day pitavastatin
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 4 mg/day pitavastatin
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 27638812

Group type: EXPERIMENTAL
Intervention: Infliximab + Methotrexate (IFX + MTX)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Methotrexate + Methylprednisolone (MTX + methylprednisolone)
Number of subjects: 79
Study: 25330142

Group type: EXPERIMENTAL
Intervention: 3 mg/kg/day enteric-coated aspirin tablets for 6 months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day enteric-coated aspirin tablets for 6 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Immediate postoperative conditions
Number of subjects: 32
Study: 23440485

Group type: EXPERIMENTAL
Intervention: Preservation of the hepatic branch of the anterior vagus nerve (HB‐AVn)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sacrifice of the hepatic branch of the anterior vagus nerve (HB‐AVn)
Number of subjects: 40
Study: 21904634

Group type: EXPERIMENTAL
Intervention: 0.1% NVC-422 topical gel
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 0.5% NVC-422 topical gel
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 1.5% NVC-422 topical gel
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: NVC-422 topical gel (all doses)
Number of subjects: 129
Study: 17998305

Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bipolar electrocautery
Number of subjects: 60
Study: 16890481

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 58
Study: 12793550

Group type: EXPERIMENTAL
Intervention: Body-exhaust suits (BES)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rotecno occlusive clothing
Number of subjects: 50
Study: 11020506

Group type: EXPERIMENTAL
Intervention: Tomcat catheter
Number of subjects: 66

Group type: COMPARATOR
Intervention: TDT catheter
Number of subjects: 66
Study: 9816202

Group type: COMPARATOR
Intervention: Carboplatin alone
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Carboplatin following Taxol pretreatment
Number of subjects: 11
Study: 1482300

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG) nebulized solution
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 31
Study: 3516509

Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine OROS (Acutrim)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study: 30222804

Group type: EXPERIMENTAL
Intervention: CLS‐TA (triamcinolone acetonide injectable suspension)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Fellow eyes (control group)
Number of subjects: 14
Study: 27287210

Group type: EXPERIMENTAL
Intervention: Doxycycline (oral, 4 weeks)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo (oral, 4 weeks)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Alclometasone (topical) plus VSL#3 (oral)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: VSL#3 (oral)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Placebo (for alclometasone and VSL#3)
Number of subjects: 173
Study: 25241229

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CHRT) with fluorouracil (5 FU) infusion and cisplatin, associated with radiotherapy (50 Gy)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Gemcitabine plus oxaliplatin (GEMOX) for 6 months (CH arm)
Number of subjects: 34
Study: 22857987

Group type: EXPERIMENTAL
Intervention: Mental practice in addition to occupational therapy
Number of subjects: 30
Study: 19858313

Group type: EXPERIMENTAL
Intervention: Project ACTS educational materials
Number of subjects: 425

Group type: COMPARATOR
Intervention: Donation education materials currently available to consumers
Number of subjects: 425
Study: 18376338

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS) at 1 Hz, 1200 stim/day for five days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 16398602

Group type: EXPERIMENTAL
Intervention: 5-minute forearm/hand massage of effleurage and friction
Number of subjects: 52

Group type: COMPARATOR
Intervention: 5 minutes of passive shoulder and elbow range of motion
Number of subjects: 52

Group type: COMPARATOR
Intervention: 5 minutes of nonintervention rest
Number of subjects: 52
Study: 12551706

Group type: EXPERIMENTAL
Intervention: Levodopa/benserazide (200/50 mg) with a high-fat breakfast
Number of subjects: 19

Group type: COMPARATOR
Intervention: Levodopa/benserazide (200/50 mg) in fasting conditions
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Levodopa/benserazide (200/50 mg) with food
Number of subjects: 19
Study: 10513411

Group type: EXPERIMENTAL
Intervention: Telviran (800 mg acyclovir)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Zovirax (800 mg acyclovir)
Number of subjects: 24
Study: 7884432

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 0
Study: 2028627

Group type: EXPERIMENTAL
Intervention: SR PPA 75 mg/d
Number of subjects: 14

Group type: COMPARATOR
Intervention: Indomethacin and placebo
Number of subjects: 14
Study: 6106501

Group type: EXPERIMENTAL
Intervention: Combined sedative and anxiolytic preparations (specific combinations not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amylobarbitone sodium (established hypnotic)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobazam/dichloralphenazone (anxiolytic/sedative combination)
Number of subjects: 0
Study: 30467827

Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 176

Group type: COMPARATOR
Intervention: LMA Protector
Number of subjects: 176
Study: 28675660

Group type: EXPERIMENTAL
Intervention: First-line intercalated chemotherapy + erlotinib, maintenance erlotinib in patients with EGFR mutations
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: First-line afatinib, maintenance afatinib in patients with EGFR deletion 19
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy + bevacizumab, maintenance bevacizumab in EGFR wild-type patients
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Chemotherapy + conatumumab, maintenance conatumumab in patients with squamous histology
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Chemotherapy + cetuximab, maintenance cetuximab or chemotherapy + necitumumab, maintenance necitumumab in EGFR FISH-positive patients with squamous histology
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy + bevacizumab, maintenance bevacizumab or first-line sequential chemotherapy + gefitinib, maintenance gefitinib in patients clinically enriched for EGFR mutations with nonsquamous histology
Number of subjects: 56

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 56
Study: 26393645

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (<40 g/day), n = 75
Number of subjects: 148

Group type: COMPARATOR
Intervention: Low-fat diet (<30% kcal/day from total fat, <7% saturated fat), n = 73
Number of subjects: 148
Study: 23531208

Group type: EXPERIMENTAL
Intervention: RBC transfusion of more than 3 units (high transfusion requirement group, 62 patients)
Number of subjects: 502

Group type: EXPERIMENTAL
Intervention: RBC transfusion of 3 units or fewer (low transfusion requirement group, 241 patients)
Number of subjects: 502

Group type: COMPARATOR
Intervention: No RBC transfusion (199 patients)
Number of subjects: 502
Study: 20608806

Group type: EXPERIMENTAL
Intervention: Breastfeeding education/support offered at home on day 3 postpartum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard breastfeeding education provided to all women in the hospital (control group)
Number of subjects: 60
Study: 19574500

Group type: EXPERIMENTAL
Intervention: Preinduced quadriceps fatigue (via electrostimulation-induced contractions)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fresh state (no quadriceps fatigue)
Number of subjects: 24
Study: 17295728

Group type: EXPERIMENTAL
Intervention: Needle acupuncture
Number of subjects: 109

Group type: COMPARATOR
Intervention: Aromatherapy
Number of subjects: 109
Study: 15385382

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 37.5 microg (Group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 75 microg (Group 3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intrathecal clonidine 150 microg (Group 4)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Isobaric 0.5% bupivacaine, 18 mg plus saline (Group 1, control)
Number of subjects: 80
Study: 11350502

Group type: EXPERIMENTAL
Intervention: 0.01% P‐113 mouthrinse
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 0.05% P‐113 mouthrinse
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 159
Study: 9699431

Group type: EXPERIMENTAL
Intervention: Patient-controlled TENS at the injection site
Number of subjects: 100

Group type: COMPARATOR
Intervention: Topical anaesthesia (2 min application of 20% benzocaine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 100
Study: 7987557

Group type: EXPERIMENTAL
Intervention: Exposure to coal and rock dust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biochemical tests
Number of subjects: 0
Study: 2513630

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) prophylactically
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TMP-SMZ plus colistin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neomycin plus colistin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonabsorbable agents
Number of subjects: 0
Study: 1269214

Group type: EXPERIMENTAL
Intervention: Experimental soft gelatin formulations of digoxin in solution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capsules of digoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tablets of digoxin
Number of subjects: 0
Study: 31698889

Group type: EXPERIMENTAL
Intervention: Visnadine Emulgel
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 27809380

Group type: EXPERIMENTAL
Intervention: Encapsulated placenta (n = 10)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Beef placebo (n = 13)
Number of subjects: 23
Study: 25686254

Group type: EXPERIMENTAL
Intervention: Technical training programme for the non-preferred foot
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no specific training)
Number of subjects: 71
Study: 23135877

Group type: EXPERIMENTAL
Intervention: Parent Management Training‐Oregon Model (PMTO)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Wait-list condition (WLC)
Number of subjects: 96
Study: 21621193

Group type: EXPERIMENTAL
Intervention: Standard tongue-training task (1 hour with fixed training parameters)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Modulation tongue-training task (1 hour with modulation of training parameters every 20 min)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Ability to roll the tongue
Number of subjects: 44
Study: 17964548

Group type: EXPERIMENTAL
Intervention: Venlafaxine treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 15
Study: 16816536

Group type: EXPERIMENTAL
Intervention: LV5FU2
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: ldLV5FU2
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: HD-FU
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Tomudex
Number of subjects: 294
Study: 12615868

Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g every 8 h (C3 x 2)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Ceftazidime 2 g as a loading dose, followed by ceftazidime 2 g over 7 h every 12 h (C2 x 2)
Number of subjects: 81
Study: 10669372

Group type: EXPERIMENTAL
Intervention: Meningococcal C conjugate (MCC) vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meningococcal AC polysaccharide (MACP) vaccine
Number of subjects: 0
Study: 9119865

Group type: EXPERIMENTAL
Intervention: Wrought Co‐28Cr‐6Mo‐0.2C metal‐on‐metal articulations
Number of subjects: 55

Group type: COMPARATOR
Intervention: Ceramic‐on‐polyethylene hips (control group)
Number of subjects: 55